Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Upgraded to Buy at Zacks Investment Research

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, October 17th. The brokerage currently has a $11.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 2.80% from the stock’s current price.

According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters.”

A number of other brokerages also recently issued reports on SCMP. Maxim Group set a $23.00 price objective on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Leerink Swann started coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, August 21st. They issued an “outperform” rating and a $15.00 target price on the stock. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $16.50.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded up $0.15 during trading hours on Tuesday, reaching $10.70. 582,572 shares of the company were exchanged, compared to its average volume of 486,611. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market cap of $495.52, a price-to-earnings ratio of 7.23, a P/E/G ratio of 3.27 and a beta of 1.38.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 EPS. research analysts predict that Sucampo Pharmaceuticals will post 1.08 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://baseballnewssource.com/markets/sucampo-pharmaceuticals-inc-scmp-upgraded-at-zacks-investment-research/1722335.html.

In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jason Patrick Meyenburg acquired 4,000 shares of the stock in a transaction dated Wednesday, September 6th. The stock was acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Advisor Group Inc. lifted its stake in shares of Sucampo Pharmaceuticals by 45.1% in the 3rd quarter. Advisor Group Inc. now owns 20,475 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 6,361 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth approximately $207,000. Prudential Financial Inc. lifted its stake in shares of Sucampo Pharmaceuticals by 871.6% in the 3rd quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after purchasing an additional 368,090 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in shares of Sucampo Pharmaceuticals by 33.0% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 64,269 shares of the biopharmaceutical company’s stock worth $758,000 after purchasing an additional 15,944 shares during the period. Finally, Dupont Capital Management Corp purchased a new stake in Sucampo Pharmaceuticals in the 3rd quarter worth approximately $635,000. Hedge funds and other institutional investors own 55.76% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.